Sarah Willis1, Amanda D Castel, Tashrik Ahmed, Christie Olejemeh, Lawrence Frison, Michael Kharfen. 1. *The George Washington University School of Public Health and Health Services, Department of Epidemiology and Statistics, Washington, DC; and †District of Columbia Department of Health, HIV/AIDS, Hepatitis, STD, TB Administration, Washington, DC.
Abstract
BACKGROUND: The District of Columbia Department of Health funds facilities to provide HIV medical case management (MCM), inclusive of linkage, engagement in care, and treatment adherence support. The objective of this analysis was to identify the differences in the clinical outcomes among HIV-infected persons receiving care at MCM-funded facilities compared with those in nonfunded facilities. METHODS: Newly diagnosed and prevalent HIV-infected persons were identified from the District of Columbia Department of Health surveillance system. Clinical outcomes of interest were linkage, retention in care, and viral suppression. Bivariate analyses and random effects logistic regression were used to examine the differences in demographics and clinical outcomes of persons receiving care at MCM-funded and nonfunded facilities. RESULTS: Among 5631 prevalent cases, 56.7% received care at MCM-funded facilities of which 76.2% were retained in care, and 70.6% achieved viral suppression. Those receiving care in MCM-funded facilities were significantly more likely to be retained in care [adjusted odds ratio (aOR) 4.13; 95% confidence interval (CI): 1.93 to 8.85] and as likely (aOR 1.06; 95% CI: 0.68 to 1.62) to be virally suppressed than persons receiving care in nonfunded facilities. Among 789 newly diagnosed persons, those diagnosed in MCM-funded facilities were not significantly more likely to be linked to care within 3 months (aOR 0.50; 95% CI: 0.21 to 1.18) than those diagnosed in nonfunded facilities. DISCUSSION: This study provides evidence that MCM may be beneficial to HIV-infected persons in DC by improving retention in care. Further identification of the specific services providing the most benefit to clients is needed, including a better understanding of the complex relationship between retention and viral suppression.
BACKGROUND: The District of Columbia Department of Health funds facilities to provide HIV medical case management (MCM), inclusive of linkage, engagement in care, and treatment adherence support. The objective of this analysis was to identify the differences in the clinical outcomes among HIV-infectedpersons receiving care at MCM-funded facilities compared with those in nonfunded facilities. METHODS: Newly diagnosed and prevalent HIV-infectedpersons were identified from the District of Columbia Department of Health surveillance system. Clinical outcomes of interest were linkage, retention in care, and viral suppression. Bivariate analyses and random effects logistic regression were used to examine the differences in demographics and clinical outcomes of persons receiving care at MCM-funded and nonfunded facilities. RESULTS: Among 5631 prevalent cases, 56.7% received care at MCM-funded facilities of which 76.2% were retained in care, and 70.6% achieved viral suppression. Those receiving care in MCM-funded facilities were significantly more likely to be retained in care [adjusted odds ratio (aOR) 4.13; 95% confidence interval (CI): 1.93 to 8.85] and as likely (aOR 1.06; 95% CI: 0.68 to 1.62) to be virally suppressed than persons receiving care in nonfunded facilities. Among 789 newly diagnosed persons, those diagnosed in MCM-funded facilities were not significantly more likely to be linked to care within 3 months (aOR 0.50; 95% CI: 0.21 to 1.18) than those diagnosed in nonfunded facilities. DISCUSSION: This study provides evidence that MCM may be beneficial to HIV-infectedpersons in DC by improving retention in care. Further identification of the specific services providing the most benefit to clients is needed, including a better understanding of the complex relationship between retention and viral suppression.
Authors: D L Paterson; S Swindells; J Mohr; M Brester; E N Vergis; C Squier; M M Wagener; N Singh Journal: Ann Intern Med Date: 2000-07-04 Impact factor: 25.391
Authors: Lytt I Gardner; Lisa R Metsch; Pamela Anderson-Mahoney; Anita M Loughlin; Carlos del Rio; Steffanie Strathdee; Stephanie L Sansom; Harvey A Siegal; Alan E Greenberg; Scott D Holmberg Journal: AIDS Date: 2005-03-04 Impact factor: 4.177
Authors: Jason A Craw; Lytt I Gardner; Gary Marks; Richard C Rapp; Jeff Bosshart; Wayne A Duffus; Amber Rossman; Susan L Coughlin; DeAnn Gruber; Lauretta A Safford; Jon Overton; Karla Schmitt Journal: J Acquir Immune Defic Syndr Date: 2008-04-15 Impact factor: 3.731
Authors: Judith A Aberg; Jonathan E Kaplan; Howard Libman; Patricia Emmanuel; Jean R Anderson; Valerie E Stone; James M Oleske; Judith S Currier; Joel E Gallant Journal: Clin Infect Dis Date: 2009-09-01 Impact factor: 9.079
Authors: Andrew J Wawrzyniak; Allan E Rodríguez; Anthony E Falcon; Anindita Chakrabarti; Alexa Parra; Jane Park; Kathleen Mercogliano; Kira Villamizar; Michael A Kolber; Daniel J Feaster; Lisa R Metsch Journal: J Acquir Immune Defic Syndr Date: 2015-05-01 Impact factor: 3.731
Authors: Christine Oramasionwu; Stacy Cooper Bailey; Terence L Johnson; Lu Mao Journal: AIDS Res Hum Retroviruses Date: 2014-11-11 Impact factor: 2.205
Authors: Alan E Greenberg; David W Purcell; Christopher M Gordon; Rebecca J Barasky; Carlos del Rio Journal: J Acquir Immune Defic Syndr Date: 2015-05-01 Impact factor: 3.731
Authors: Kathryn A Risher; Sunaina Kapoor; Alice Moji Daramola; Gabriela Paz-Bailey; Jacek Skarbinski; Kate Doyle; Kate Shearer; David Dowdy; Eli Rosenberg; Patrick Sullivan; Maunank Shah Journal: AIDS Behav Date: 2017-07
Authors: Alan E Greenberg; David W Purcell; Christopher M Gordon; Stephen Flores; Cynthia Grossman; Holly H Fisher; Rebecca J Barasky Journal: J Acquir Immune Defic Syndr Date: 2013-11-01 Impact factor: 3.731
Authors: McKaylee M Robertson; Kate Penrose; Mary K Irvine; Rebekkah S Robbins; Sarah Kulkarni; Sarah L Braunstein; Levi Waldron; Graham Harriman; Denis Nash Journal: J Acquir Immune Defic Syndr Date: 2019-01-01 Impact factor: 3.731